{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:18:53Z","timestamp":1780503533225,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.curtheres.2021.100657","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T10:03:36Z","timestamp":1638180216000},"page":"100657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Post-Marketing Surveillance of a generic Oxaliplatin (Alvoxal\u24c7) in Iranian Patients with Cancer"],"prefix":"10.1016","volume":"96","author":[{"given":"Farhad","family":"Shahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Gorji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Payandeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Vaezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharareh","family":"Seifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Baari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Khalili-Dizaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mehdi","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Salimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosein","family":"Kamranzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Shazad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Salari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davoud Oulad","family":"Dameshghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Sarkheil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrzad","family":"Mirzania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Anjidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2021.100657_bib0001","unstructured":"U.S. Food and Drug Administration. 2020. Postmarket Drug Safety Information For Patients And Providers. [online] Available at: <https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/postmarket-drug-safety-information-patients-and-providers>[Accessed 2 August 2020]."},{"issue":"2 Suppl 5","key":"10.1016\/j.curtheres.2021.100657_bib0002","first-page":"4","article-title":"Oxaliplatin: mechanism of action and antineoplastic activity","volume":"25","author":"Raymond","year":"1998","journal-title":"Seminars in oncology"},{"issue":"5","key":"10.1016\/j.curtheres.2021.100657_bib0003","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1124\/mol.54.5.770","article-title":"Juniewicz P. Sequence-and region-specificity of oxaliplatin adducts in naked and cellular DNA","volume":"54","author":"Woynarowski","year":"1998","journal-title":"Molecular pharmacology"},{"issue":"9","key":"10.1016\/j.curtheres.2021.100657_bib0004","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/00001813-199710000-00009","article-title":"Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers","volume":"8","author":"Raymond","year":"1997","journal-title":"Anti-cancer drugs"},{"issue":"4","key":"10.1016\/j.curtheres.2021.100657_bib0005","first-page":"575","article-title":"Evaluation of in vitro cytotoxicity of oxaliplatin and 5-fluorouracil in human colon cancer cell lines: combination versus sequential exposure","volume":"25","author":"Failli","year":"2011","journal-title":"Journal of biological regulators and homeostatic agents"},{"issue":"16","key":"10.1016\/j.curtheres.2021.100657_bib0006","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.curtheres.2021.100657_bib0007","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/TCRM.S3583","article-title":"Role of oxaliplatin in the treatment of colorectal cancer","volume":"5","author":"Comella","year":"2009","journal-title":"Therapeutics and clinical risk management"},{"key":"10.1016\/j.curtheres.2021.100657_bib0008","unstructured":"Gco.iarc.fr. 2020. Cancer Today. [online] Available at: <https:\/\/gco.iarc.fr\/today\/online-analysis table?v=2018&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=41&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1>[Accessed 1 August 2020]."},{"key":"10.1016\/j.curtheres.2021.100657_bib0009","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.curtheres.2021.100657_bib0010","unstructured":"Vizhub.healthdata.org. 2020. GBD Compare | IHME Viz Hub. [online] Available at: <https:\/\/vizhub.healthdata.org\/gbd-compare\/>[Accessed 2 August 2020]."},{"key":"10.1016\/j.curtheres.2021.100657_bib0011","unstructured":"Nccn.org. 2020. [online] Available at: <https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf>[Accessed 2 August 2020]."},{"issue":"23","key":"10.1016\/j.curtheres.2021.100657_bib0012","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1016\/j.curtheres.2021.100657_bib0013","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"35","key":"10.1016\/j.curtheres.2021.100657_bib0014","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study","volume":"33","author":"Andr\u00e9","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.curtheres.2021.100657_bib0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/bjc.1998.428","article-title":"Oxaliplatin in practice","volume":"77","author":"Misset","year":"1998","journal-title":"British journal of cancer"},{"issue":"19","key":"10.1016\/j.curtheres.2021.100657_bib0016","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2165\/00003495-200363190-00013","article-title":"Oxaliplatin","volume":"63","author":"Simpson","year":"2003","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.curtheres.2021.100657_bib0017","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2003.11.045","article-title":"Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer","volume":"21","author":"Ramanathan","year":"2003","journal-title":"Journal of clinical oncology"},{"key":"10.1016\/j.curtheres.2021.100657_bib0018","unstructured":"Uptodate.com; Oxaliplatin: Drug information. 2020. Uptodate. [online] Available at: <https:\/\/www.uptodate.com\/contents\/search> [Accessed 2 August 2020]."},{"issue":"6","key":"10.1016\/j.curtheres.2021.100657_bib0019","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: a cancer journal for clinicians"},{"issue":"18","key":"10.1016\/j.curtheres.2021.100657_bib0020","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data","volume":"24","author":"Wagner","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.curtheres.2021.100657_bib0021","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4143\/crt.2011.43.3.154","article-title":"Efficacy and safety of oxaliplatin, 5-fluorouracil, and folinic acid combination chemotherapy as first-line treatment in metastatic or recurrent gastric cancer","volume":"43","author":"Kim","year":"2011","journal-title":"Cancer Research and Treatment: Official Journal of Korean Cancer Association"},{"issue":"8","key":"10.1016\/j.curtheres.2021.100657_bib0022","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.7150\/jca.28896","article-title":"Oxaliplatin-based regimen is superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer: A meta-analysis","volume":"10","author":"Zhang","year":"2019","journal-title":"Journal of Cancer"},{"issue":"1","key":"10.1016\/j.curtheres.2021.100657_bib0023","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1016\/j.curtheres.2021.100657_bib0024","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.clcc.2016.04.004","article-title":"TAS-102 safety in metastatic colorectal cancer: results from the first post-marketing surveillance","volume":"15","author":"Yoshino","year":"2016","journal-title":"Clinical colorectal cancer"},{"key":"10.1016\/j.curtheres.2021.100657_bib0025","unstructured":"nano alvand. 2020. Alvoxal. [online] Available at: <https:\/\/www.nanoalvand.com\/products\/detail\/Oxaliplatin\/117\/view\/>[Accessed 2 August 2020]."},{"key":"10.1016\/j.curtheres.2021.100657_bib0026","unstructured":"https:\/\/www.fda.gov.ir\/en"},{"key":"10.1016\/j.curtheres.2021.100657_bib0027","series-title":"Sample Size Tables for Clinical Studies","author":"Machin","year":"1997"},{"issue":"10","key":"10.1016\/j.curtheres.2021.100657_bib0028","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1517\/14656566.5.10.2159","article-title":"A review of oxaliplatin and its clinical use in colorectal cancer","volume":"5","author":"Grothey","year":"2004","journal-title":"Expert opinion on pharmacotherapy"},{"issue":"16","key":"10.1016\/j.curtheres.2021.100657_bib0029","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.curtheres.2021.100657_bib0030","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"Journal of clinical oncology"},{"issue":"1","key":"10.1016\/j.curtheres.2021.100657_bib0031","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1016\/j.curtheres.2021.100657_bib0032","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clcc.2011.09.001","article-title":"Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies","volume":"11","author":"Sugihara","year":"2012","journal-title":"Clinical colorectal cancer"},{"issue":"2","key":"10.1016\/j.curtheres.2021.100657_bib0033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1743-7563.2009.01199.x","article-title":"Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: the MASCOT study","volume":"5","author":"LEE","year":"2009","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"28","key":"10.1016\/j.curtheres.2021.100657_bib0034","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"suppl_5","key":"10.1016\/j.curtheres.2021.100657_bib0035","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Annals of Oncology"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X21000357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X21000357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:58:18Z","timestamp":1757897898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X21000357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":35,"alternative-id":["S0011393X21000357"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2021.100657","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-Marketing Surveillance of a generic Oxaliplatin (Alvoxal\u24c7) in Iranian Patients with Cancer","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2021.100657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100657"}}